This segment focuses on the research, development, and clinical evaluation of targeted radiotherapies using Actinium's proprietary Antibody Radiation Conjugate (ARC) platform. The company is pioneering the use of radioisotopes, such as Actinium-225 and Iodine-131, conjugated to antibodies to deliver radiation directly to cancer cells. R&D activities include preclinical studies, IND-enabling studies, and clinical trials across various hematologic malignancies and solid tumors. The goal is to improve patient outcomes by selectively targeting cancer cells while minimizing damage to healthy tissues. This segment leverages Actinium's expertise in radioisotope handling, antibody engineering, and clinical development to create innovative cancer treatments with the potential for improved efficacy and reduced toxicity. Future opportunities include expanding the ARC platform to new targets and indications, as well as exploring combination therapies with other cancer treatments.

This segment is centered around the development of Iomab-B and Iomab-ACT for bone marrow transplant (BMT) or hematopoietic stem cell transplant (HSCT) conditioning. These targeted radiotherapies are designed to selectively eliminate malignant cells in patients with relapsed or refractory acute myeloid leukemia (AML) and other hematologic malignancies prior to BMT. Research and development efforts focus on optimizing the dosing and administration of Iomab-B and Iomab-ACT, as well as evaluating their efficacy and safety in clinical trials. The goal is to improve BMT outcomes by reducing the risk of relapse and graft-versus-host disease (GVHD). This segment addresses a critical unmet need in BMT by providing a more targeted and effective conditioning regimen compared to traditional chemotherapy or total body irradiation. Future opportunities include expanding the use of Iomab-B and Iomab-ACT to other BMT indications, such as multiple myeloma and lymphoma, as well as exploring their potential in combination with other BMT-related therapies.